Article
Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases.
CNS oncology - 1 Dec 2019
Smith-Cohn Matthew, Davidson Christian, Colman Howard, Cohen Adam L
Abstract excerpt
Aim: Therapeutic targeting of BRAF alterations in primary brain tumor patients has demonstrated clinical activity in case reports and early trials; however, there is limited high-level evidence of the efficacy. Patients & results: Targeting BRAF V600E mutations with concurrent dabrafenib and trametinib in anaplastic pleomorphic xanthoastrocytoma resulted in a transient radiographic and clinical response and no...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.